AARDAardvark Therapeutics, Inc. Common Stock

AARD Stock Price, Valuation & Chart | Aardvark Therapeutics, Inc. Common Stock

Compare

$5.950+0.03 (+0.51%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology AARD intrinsic value AARD calculated fair value vs price

Overview Financials Dividends Ratios

AARD Historical price chart

AARD Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization130.21M

PE Ratio-1.85

EPS-3.21

Trading Volume59.40K

Today's High/Low6.17/5.79

Dividend Yield0.00

52 Week High/Low17.94/3.35

Shares Outstanding21.88M

AARD Financial Statement

AARD Analyst ratings

AARD Analysis & performance metrics

AARD Company profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III…

AARD Management team

Name

Position

Bryan Jones Ph.D.COO

Chief Operating Officer

Tom Bicsak Ph.D.

Head of Regulatory Affairs & Quality

Andreas Niethammer M.D., Ph.D.

Head of Translational Medicine

Manasi Sinha Jaiman M.D., M.P.H.

Chief Medical Officer

Nelson B. Sun M.B.A.CFO

Chief Financial Officer

Dvorit Samid Ph.D.

Executive Vice President of Medical Affairs

Zhenhuan Zheng Ph.D.

Chief Research Officer

Tien-Li Lee M.D.CEO

Chief Executive Officer, Secretary & Director

Name

Position

Bryan Jones Ph.D.COO

Chief Operating Officer

Tom Bicsak Ph.D.

Head of Regulatory Affairs & Quality

Andreas Niethammer M.D., Ph.D.

Head of Translational Medicine

Manasi Sinha Jaiman M.D., M.P.H.

Chief Medical Officer

Nelson B. Sun M.B.A.CFO

Chief Financial Officer

Dvorit Samid Ph.D.

Executive Vice President of Medical Affairs

Zhenhuan Zheng Ph.D.

Chief Research Officer

Tien-Li Lee M.D.CEO

Chief Executive Officer, Secretary & Director

Management Team

Bryan Jones Ph.D.COO

Chief Operating Officer

Tom Bicsak Ph.D.

Head of Regulatory Affairs & Quality

Andreas Niethammer M.D., Ph.D.

Head of Translational Medicine

Manasi Sinha Jaiman M.D., M.P.H.

Chief Medical Officer

Nelson B. Sun M.B.A.CFO

Chief Financial Officer

Dvorit Samid Ph.D.

Executive Vice President of Medical Affairs

Zhenhuan Zheng Ph.D.

Chief Research Officer

Tien-Li Lee M.D.CEO

Chief Executive Officer, Secretary & Director

Management

Bryan Jones Ph.D.COO

Chief Operating Officer

Tom Bicsak Ph.D.

Head of Regulatory Affairs & Quality

Andreas Niethammer M.D., Ph.D.

Head of Translational Medicine

Manasi Sinha Jaiman M.D., M.P.H.

Chief Medical Officer

Nelson B. Sun M.B.A.CFO

Chief Financial Officer

Dvorit Samid Ph.D.

Executive Vice President of Medical Affairs

Zhenhuan Zheng Ph.D.

Chief Research Officer

Tien-Li Lee M.D.CEO

Chief Executive Officer, Secretary & Director

Total 8 executives

AARD Frequently asked questions

What is Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Price?

Current stock price of Aardvark Therapeutics, Inc. Common Stock (AARD) stock is $5.950. The stock price is +0.51% higher in the session. The intraday range can be seen from this page. Volume of Aardvark Therapeutics, Inc. Common Stock (AARD) stock is 59.40K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Aardvark Therapeutics, Inc. Common Stock (AARD) stock price going up or down today?

The stock price of Aardvark Therapeutics, Inc. Common Stock (AARD) can change with earnings, company news, and overall market sentiment. Aardvark Therapeutics, Inc. Common Stock operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Aardvark Therapeutics, Inc. Common Stock stock expensive at its current price?

Whether Aardvark Therapeutics, Inc. Common Stock looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for AARD on this page is -1.85. EPS on this page is -3.21. Compare those figures with peers and growth expectations before deciding if the current Aardvark Therapeutics, Inc. Common Stock price is justified.

How has the stock price of Aardvark Therapeutics, Inc. Common Stock (AARD) performed historically?

Historical performance for Aardvark Therapeutics, Inc. Common Stock (AARD) is shown on the price chart on this page. Review multi-period moves alongside volume to see how AARD reacted to past earnings and market events.

Should I buy Aardvark Therapeutics, Inc. Common Stock (AARD) stock, at this price?

Buying Aardvark Therapeutics, Inc. Common Stock (AARD) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.